Early MS drugs show different costs as disease progresses, study finds

A Swedish national study tracking newly diagnosed multiple sclerosis patients reveals how three common first-line treatments—interferons, glatiramer acetate, and natalizumab—affect healthcare spending over time. The findings could help payers and health systems optimize treatment decisions and budget forecasts for MS care.

Originaltitel: Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab